Lund University is celebrating 350 years. Read more on lunduniversity.lu.se

Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.

β-Blocker Use and Mortality in COPD Patients After Myocardial Infarction: A Swedish Nationwide Observational Study.

Author:
  • Pontus Andell
  • David Erlinge
  • Gustav Smith
  • Johan Sundström
  • Bertil Lindahl
  • Stefan James
  • Sasha Koul
Publishing year: 2015
Language: English
Pages: 001611-001611
Publication/Series: Journal of the American Heart Association
Volume: 4
Issue: 4
Document type: Journal article
Publisher: Wiley-Blackwell

Abstract english

Patients with myocardial infarction (MI) and concomitant chronic obstructive pulmonary disease (COPD) constitute a high-risk group with increased mortality. β-Blocker therapy has been shown to reduce mortality, prevent arrhythmias, and delay heart failure development after an MI in broad populations. However, the effect of β-blockers in COPD patients is less well established and they may also be less treated due to fear of adverse reactions. We investigated β-blocker prescription at discharge in patients with COPD after MI.

Keywords

  • Cardiac and Cardiovascular Systems

Other

Published
  • ISSN: 2047-9980
E-mail: gustav [dot] smith [at] med [dot] lu [dot] se

Associate professor

Cardiology

+46 46 17 26 33

D1232C

32

Research project participant

Cardiovascular Epigenetics

32

Research project participant

Heart Failure and Mechanical Support

32

Project manager

Molecular Epidemiology and Cardiology

+46 46 17 26 33

32

Lund University Diabetes Centre, CRC, SUS Malmö, Entrance 72, House 91:12. SE-205 02 Malmö. Telephone: +46 40 39 10 00